| Drug Name |
Entecavir |
| Drug ID |
BADD_D00774 |
| Description |
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005. |
| Indications and Usage |
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. |
| Marketing Status |
Prescription |
| ATC Code |
J05AF10 |
| DrugBank ID |
DB00442
|
| KEGG ID |
D04008
|
| MeSH ID |
C413685
|
| PubChem ID |
135398508
|
| TTD Drug ID |
D0KR2J
|
| NDC Product Code |
42291-261; 31722-833; 69097-425; 60050-057; 43547-437; 16729-389; 60687-216; 51991-895; 42291-262; 0003-1614; 42806-659; 65862-842; 50268-289; 71921-194; 0003-1611; 63285-888; 63285-887; 68382-921; 65862-798; 70771-1020; 42806-658; 51407-065; 51991-896; 16714-718; 68382-920; 16729-388; 71921-195; 62227-101; 53104-7692; 31722-834; 16714-717; 65862-841; 0003-1612; 13612-0020; 70771-1019; 65977-0086; 62227-102; 69097-426; 51407-064; 17381-031; 66406-0331; 60050-077; 76397-001; 65162-446; 65162-449; 43547-436 |
| Synonyms |
entecavir | Baraclude |
